Incannex announced the first patient dosing in the DReAMzz Phase 2 dose-optimization study for IHL-42X, a treatment for obstructive sleep apnea expected to further support the Phase 3 development program and the company's financial outlook.
Incannex announced the first patient dosing in the DReAMzz Phase 2 dose-optimization study for IHL-42X, a treatment for obstructive sleep apnea expected to further support the Phase 3 development program and the company's financial outlook.